Chang Carmen Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
9
Insider Buys Sum
$102.41M
Insider Sells Quantity
2
Insider Sells Sum
$17,497.07

Insider Activity of Chang Carmen

According to the SEC Form 4 filings, Chang Carmen, being in a position of

  1. 10 percent owner at Korro Bio, Inc.,
    оver the last 12 months, has bought 207100 shares for $2.3M, and sold 0 shares,
    over all time since 2024-04-22, has bought 224957 shares for $3.3M, and sold 0 shares.

Biography of Chang Carmen

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $2,300,8811100
Sells
 $000

Comparison of Insiders on Amount of Buys and Sells

2026-03-10PurchaseKorro Bio, Inc.
KRRO
10 percent owner
207,100
1.9864%
$11.11$2.3M+6.71%
2024-04-22PurchaseKorro Bio, Inc.
KRRO
10 percent owner
17,857
0.205%
$56.00$999,992-40.03%
2023-07-17PurchaseSavara Inc.
SVRA
10 percent owner
333,333
0.2084%
$3.00$999,999+32.8%
2023-03-15SaleCoursera, Inc.
COUR
director
1,226
0.0008%
$11.82$14,497+38.01%
2021-10-18PurchaseTrevi Therapeutics, Inc.
TRVI
10 percent owner
1.85M
11.1305%
$1.62$3M+63.35%
2021-06-28PurchaseMonte Rosa Therapeutics, Inc.
GLUE
10 percent owner
1.05M
20.5778%
$19.00$19.95M-7.95%
2021-03-16PurchaseMarker Therapeutics, Inc.
MRKR
10 percent owner
5.71M
9.5207%
$1.75$10M-4.3%
2020-04-03SaleTrevi Therapeutics, Inc.
TRVI
10 percent owner
1,128
0.0062%
$2.66$3,000+19.07%
2019-07-22PurchaseMirum Pharmaceuticals, Inc.
MIRM
10 percent owner
900,000
5.3814%
$15.00$13.5M+5.09%
2019-05-09PurchaseTrevi Therapeutics, Inc.
TRVI
10 percent owner
5M
34.6117%
$10.00$50M-42.9%
Total: 10
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.